Skip to search formSkip to main contentSkip to account menu

CS 023

Known as: CS-023, CS023 cpd, RO4908463 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tomopenem

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa.
The postantibiotic effect (PAE) of tomopenem was determined after a 2 h exposure of two strains of meticillin-susceptible and… 
2008
2008
Potent In Vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa
ABSTRACT Tomopenem (formerly CS-023) is a novel 1β-methylcarbapenem with broad-spectrum coverage of gram-positive and gram… 
2008
2008
In Vivo Pharmacodynamic Activity of Tomopenem (formerly CS-023) Against Pseudomonas aeruginosa and MRSA in Murine Thigh Infection Model
2008
2008
In Vivo Efficacy of Tomopenem (formerly CS-023) Human-Simulated Exposure Against Pseudomonas aeruginosa and MRSA
2006
2006
Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem
The plasma half-life of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, is longer than that of meropenem in animals… 
2004
2004
Pharmacodynamics of RO4908463 (CS-023) for the Empiric Treatment of Nosocomial Pneumonia
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)